

DRUG-RESISTANT TUBERCULOSIS IN THE AMERICAS

Globally:

- There were an estimated 600,000 new cases of RR*/MDR-TB in 2016.**
- The crisis in the detection and treatment of MDR-TB continues. Of the 600,000 cases estimated in 2016, only 125,000 (20%) were reported. Three countries reported 50% of the cases: India, China, and the Russian Federation.
- The most recent data on treatment outcomes (2014), show that the success rate was 54% for RR/MDR-TB and 30% for XDR-TB,*** compared to 83% for drug-susceptible TB (2015).
- As part of the efforts to improve the outcomes of patients with MDR/XDR-TB, 35 countries have implemented the use of shorter regimens for RR/MDR-TB; 89 countries are using bedaquiline, and delamanid is used in 54 countries.

* RR-TB: rifampicin-resistant tuberculosis

** MDR-TB: multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampicin)


*** XDR-TB: MDR-TB + resistance to any fluoroquinolone and at least one of the three injectable second-line drugs.

In the Americas (2016):

- There were an estimated 8,100 (6,700-12,000) cases of RR/MDR-TB, and 3,731 (46% of the estimate) were diagnosed.
- 90% of the estimated cases of RR/MDR-TB are found in 10 countries of the Region. Peru and Brazil account for 51% of the estimated cases.
- Of the 3,731 cases of RR/MDR-TB diagnosed, 94% began treatment.
- Although access to diagnosis through DST* has increased (40% among new cases and 34% in those previously treated), coverage is still low.
- 112 cases of XDR-TB were diagnosed and reported by 10 countries in the Region.


* Drug Susceptibility Testing

Detection and Treatment of RR/MDR-TB cases in the Americas, 2011-2016



Diagnosis of RR/MDR/XDR-TB

- **26** countries have implemented DST
- **11** countries perform DST in automated liquid culture media
- **15** countries have implemented LPA* for susceptibility testing
- **28** countries have implemented the Xpert MTB/RIF assay**



* LPA: system of nucleic acid amplification and hybridization on strips with immobilized probes


** Xpert MTB/RIF: Molecular test based on real-time PCR in a closed cartridge

Treatment of RR/MDR/XDR-TB:


- 3,344 patients with RR/MDR-TB started treatment in 2014. The treatment success rate (46%) is negatively affected by the high proportion of patients lost to follow-up (21%), or not evaluated (20%).
- Of the 150 patients with XDR-TB who began treatment in 2014, the treatment success rate fell to 48% with respect to the previous year, due to the increase in the number of deceased patients (12%), those lost to follow-up (13%), and those not evaluated (11%).
- The results of the evaluated cohorts show that patient-centered care aimed at boosting treatment adherence must be strengthened.

Treatment Outcomes in RR/MDR-TB and XDR-TB Region of the Americas 2007-2014

MDR-TB



XDR-TB



Source: WHO Tuberculosis Global Report 2017

www.paho.org/tuberculosis

© PAHO/WHO, 2018